Article
Screening of KRAS Mutation in Pre- and Post-Surgery Serum of Patients Suffering from Colon Cancer by COLD-PCR HRM.
Advances in experimental medicine and biology - 1 Jan 2016
Trujillo-Arribas Elena, Macher Hada C, Jiménez-Arriscado Pilar, de la Portilla Fernando, Molinero Patrocinio, Guerrero Juan M, Rubio Amalia
Abstract excerpt
Genomic characterization of cell-free circulating tumour DNA (ctDNA) may offer an opportunity to assess clonal dynamics throughout the course of a patient's illness. The existence of KRAS driver mutations in colon cancer patients is determinant to decide their treatment and to predict their outcome. DNA is extracted automatically from 400 μL of serum using the MagNa Pure Compact with the Nucleic Acid Isolation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
